What is the treatment for acute hepatitis B?

Acute hepatitis B is typically a self-limiting infection, meaning that in the majority of immunocompetent adults—approximately 95%—the immune system successfully clears the virus without requiring specific antiviral therapy. Management focuses primarily on supportive care: ensuring adequate hydration, maintaining nutritional intake, avoiding alcohol and hepatotoxic medications (such as acetaminophen/paracetamol in high doses), and monitoring for signs of clinical deterioration. Routine laboratory surveillance—including serial measurements of liver enzymes (ALT, AST), bilirubin, prothrombin time (INR), and serum albumin—is essential to assess disease severity and detect early indicators of acute liver failure.

In most cases, antiviral treatment is not indicated for acute hepatitis B. However, exceptions exist: antiviral therapy (e.g., entecavir or tenofovir disoproxil fumarate) may be considered in patients with severe or fulminant hepatitis B—characterized by markedly elevated transaminases, coagulopathy (INR ≥1.5), encephalopathy, or rapid clinical decompensation—or in immunocompromised individuals who are at higher risk for viral persistence and progression. Hospital admission is warranted for those with evidence of hepatic encephalopathy, variceal bleeding, renal impairment, or INR >2.0, given the risk of multiorgan failure.

Patients should be counseled on infection prevention—including avoidance of sharing personal items (razors, toothbrushes), safe sex practices, and no blood or needle-sharing—to prevent transmission. Close contacts should be screened for hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc); susceptible individuals require hepatitis B vaccination. Follow-up serology at 6 months post-diagnosis is recommended to confirm HBsAg clearance and development of anti-HBs, which signifies recovery and immunity.